GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Purple Biotech Ltd (XTAE:PPBT) » Definitions » Liabilities-to-Assets

Purple Biotech (XTAE:PPBT) Liabilities-to-Assets : 0.23 (As of Dec. 2023)


View and export this data going back to 1978. Start your Free Trial

What is Purple Biotech Liabilities-to-Assets?

Liabilities-to-Assets is a solvency ratio indicating how much of the company’s assets are made of liabilities, calculated as total liabilities divided by total asset. Purple Biotech's Total Liabilities for the quarter that ended in Dec. 2023 was ₪37.42 Mil. Purple Biotech's Total Assets for the quarter that ended in Dec. 2023 was ₪165.67 Mil. Therefore, Purple Biotech's Liabilities-to-Assets Ratio for the quarter that ended in Dec. 2023 was 0.23.


Purple Biotech Liabilities-to-Assets Historical Data

The historical data trend for Purple Biotech's Liabilities-to-Assets can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Purple Biotech Liabilities-to-Assets Chart

Purple Biotech Annual Data
Trend Dec14 Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
Liabilities-to-Assets
Get a 7-Day Free Trial Premium Member Only Premium Member Only 0.26 0.05 0.07 0.14 0.23

Purple Biotech Quarterly Data
Jun17 Dec17 Jun18 Dec18 Jun19 Dec19 Jun20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23
Liabilities-to-Assets Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 0.14 0.11 0.11 0.15 0.23

Competitive Comparison of Purple Biotech's Liabilities-to-Assets

For the Biotechnology subindustry, Purple Biotech's Liabilities-to-Assets, along with its competitors' market caps and Liabilities-to-Assets data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Purple Biotech's Liabilities-to-Assets Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Purple Biotech's Liabilities-to-Assets distribution charts can be found below:

* The bar in red indicates where Purple Biotech's Liabilities-to-Assets falls into.



Purple Biotech Liabilities-to-Assets Calculation

Liabilities-to-Assets ratio measures the portion of the total liabilities to the total asset. It indicates the leverage of the company, and the amount of debt the company uses in its operation.

Liabilities-to-Assets ratio is calculated by dividing total liabilities by total asset.

Purple Biotech's Liabilities-to-Assets Ratio for the fiscal year that ended in Dec. 2023 is calculated as:

Liabilities-to-Assets (A: Dec. 2023 )=Total Liabilities/Total Assets
=37.415/165.674
=0.23

Purple Biotech's Liabilities-to-Assets Ratio for the quarter that ended in Dec. 2023 is calculated as

Liabilities-to-Assets (Q: Dec. 2023 )=Total Liabilities/Total Assets
=37.415/165.674
=0.23

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Purple Biotech  (XTAE:PPBT) Liabilities-to-Assets Explanation

Liabilities-to-Assets is a solvency ratio indicating how much of the company’s assets are made of liabilities. It can vary greatly across different industries, as they have different capital structure. A high Liabilities-to-Assets ratio (more leveraged) suggests that the company might have potential solvency problems, or even a signal of financial distress. Conversely, a low Liabilities-to-Assets ratio usually indicates a healthy financial situation. However, it may also suggest that the company is not expanding or not making good use of debt.


Purple Biotech Liabilities-to-Assets Related Terms

Thank you for viewing the detailed overview of Purple Biotech's Liabilities-to-Assets provided by GuruFocus.com. Please click on the following links to see related term pages.


Purple Biotech (XTAE:PPBT) Business Description

Traded in Other Exchanges
Address
4 Oppenheimer Street, Science Park, Rehovot, ISR, 7670104
Purple Biotech Ltd is a clinical-stage company focused on advancing first-in-class therapies to overcome tumor immune evasion and drug resistance, and to create treatments for people with cancer. Its oncology pipeline includes NT219 and CM24.